However, EGFR activating mutations are detected in only about 29% of patients with NSCLC worldwide among which the highest (47%) and lowest (12%) frequencies have been observed in Asia-Pacific and Oceania regions, respectively [6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.